Natural Killer (NK) cells are critical in host defense against malignant transformation and are potent antileukemic cytotoxic effectors. In the present study, we investigated the peripheral NK function in patients with myelodysplastic syndromes (MDS). We demonstrated that the peripheral NK cell population was quantitatively normal in MDS patients. Furthermore, NK cells displayed an expression of the activating natural cytotoxicity receptors (NCR) NKp46 and NKp30 as well as NKG2D similar to that observed in donors, but exert a highly decreased constitutive cytolytic activity compared to resting normal NK cells. Although activation with IL-2 resulted in the upregulation of NKp46 expression by MDS-NK cells, their cytolytic function remained deeply altered as compared to activated donor NK cells. In addition, MDS NK cells did not proliferate in vitro, and displayed an increased rate of apoptosis in response to IL-2 stimulation although the spontaneous apoptosis was not significantly increased. Interestingly, a proportion of peripheral MDS-NK cells were derived from the MDS clone as the cytogenetic anomaly found in bone marrow karyotype was also detected in 20-50% of circulating NK cells. In conclusion, NK cells' cytolytic function and proliferative capacities in response to activation by cytokines are profoundly altered in MDS.
Introduction
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to peripheral cytopenias. 1 The French-American-British (FAB) classification 2 has been recently modified by WHO proposals 3 that distinguished eight subtypes of MDS: refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with an excess of blasts (RAEB) 1 and 2, refractory cytopenia with multilineage dysplasia (RCMD), RCMD with ringed sideroblasts, unclassifiable MDS, and MDS with isolated del(5q). During evolution, progressive bone marrow failure occurs and transformation toward acute leukemia is seen in one-third of cases. 4 Treatment of MDS is still unsatisfactory, and, to date, allogeneic stem cell transplantation is the only curative treatment. 5 However, only a minority of MDS patients are eligible for allogeneic transplantation, because of both advanced median age and the availability of a suitable donor.
Immunologic abnormalities have been described with a higher incidence than expected in MDS, including hypo-or hypergammaglobulinemia, monoclonal gammopathy, autoantibodies or autoimmune diseases. 6 Peripheral lymphopenia and abnormal B-or T-cell functions have also been described. The immune system also seems to contribute, in some cases, to the progressive cytopenias observed in MDS. Indeed, the increased apoptosis reported in bone marrow myeloid progenitors in MDS can be triggered by proinflammatory cytokines released by macrophages and/or lymphoid T cells of the microenvironment. 7 Furthermore, immunosuppressive therapy in MDS patients can improve peripheral cytopenias in some cases. 8 So far our knowledge on NK cell function in MDS patients remains very poor as the few studies reported were mainly performed on total peripheral blood mononucleated cells (PBMC) and did not take into account the recent advances in the understanding of NK cell biology. 9, 10 It is now established that the cytolytic function of human natural killer (NK) cells is regulated by the expression of a series of membrane receptors that either block or enhance the NK-mediated cytotoxicity. 11 Human inhibitory NK receptors include killer immunoglobulinlike receptors (KIRs) and the CD94/NKG2A heterodimer 12 that recognize MHC class-I molecules and protect normal host cells from lysis by NK cells. 13 On the other hand, activation of NK cells involves non-MHC class-I-specific activating receptors, the natural cytotoxicity receptors (NCR).
14 Three of these molecules belonging to the immunoglobulin superfamily (NKp46, NKp30 and NKp44) have been identified. NKp46 and NKp30 are selectively expressed by NK cells, and their engagement induces the NK cytolytic activity. 15, 16 NCRs whose ligands are not yet identified play a crucial role in NK cell-mediated recognition and the killing of autologous and allogeneic tumor cells. 14 A clear correlation exists between the level of NCR expression and the magnitude of natural cytotoxicity of NK cells.
17 NKG2D is another activating receptor expressed by NK cells, g/d T cells and CD8 þ T cells. 18 In contrast to the NCRs, at least some ligands for NKG2D have been identified and are the non-MHC class-I chain-related molecules (MICs) and the UL-16-binding proteins (ULBPs). 19 NK cells constitutively express NKG2D, without correlation with the NCR expression pattern.
In the present study, the phenotype and cytolytic function of NK cells derived from MDS patients (thereafter termed MDS-NK cells) were investigated. We analyzed MDS-NK cells as these effectors could play a major role in the control and clearance of leukemic cells because of their critical role in host defense against malignant transformation through lymphokine secretion and cytolytic activity. 20 Indeed, it has been shown that in acute myelogenous leukemia (AML), NK cell activity positively correlated with relapse-free survival in patients in complete remission. 21 Activated NK cells also emerge as a form of cell therapy that may enhance efficacy and safety of allogeneic hematopoietic stem cell transplantation.
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Our data indicate that NK population was found quantitatively normal in MDS patients. The expression of NCR by MDS-NK cells is similar to that of donor NK cells but they display a decreased cytolytic function, which is not increased in response to IL-2 activation. We also showed that in vitro survival and proliferation were severely reduced because of an ex vivo increased apoptosis of MDS-NK cells following in vitro stimulation by IL-2.
Materials and methods

Patients and controls
Peripheral blood samples were obtained from 40 MDS patients and 10 donors after informed consent. Median age of MDS patients was 72 years (range, 40-93 years) and 24 were men. The patients studied were classified according to the WHO classification: 13 (RA) patients studied had RA, 6 RARS, 12 RAEB-1, 7 RAEB-2 and 2 MDS/AML. Median neutrophil, hemoglobin and platelet counts at the time of blood sample collection were 0.11 Â 10 9 /l (range, 0. 
Cell preparations and cultures
PBMC were isolated from blood samples using Ficoll Lymphoprep (Nicomed Pharma, Oslo, Norway) density gradient centrifugation. Purified NK cells were obtained after depletion using a combination of mouse and rat monoclonal antibodies bound in bispecific antibody complexes directed against human hematopoietic cells (CD3, CD4, CD19, CD36, CD66b) and glycophorin A on red blood cells (RosetteSept, Stemcell Technologies Inc., Vancouver, Canada). The cells labeled with tetrameric antibody complexes are crosslinked to red blood cells and depleted after Ficoll Lymphoprep density gradient Altered NK cell functions in MDS patients J-J Kiladjian et al centrifugation. Purity of the NK cell fraction obtained from MDS assessed by flow cytometry (CD56 þ /CD16 þ /CD3À) was variable (70-90%). PBMC and immunoselected NK cells were cultured in RPMI 1640 medium supplemented with 10% human serum (Institut Jacques Boy, Reims, France) at the concentration of 7.10 5 cells/ml, and activated in vitro in the presence of recombinant human IL-2 (500 U/ml) (Aventis, Romainville, France). The K562 cell line was grown in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) (Stem cell Technologies, Vancouver, Canada) and diluted twice a week at 10 5 cells/ml.
Immunophenotyping
The following fluorescein isothiocyanate (FITC), phycoerythrin (PE) or phycoerythrin-cyanin (PE-Cy5) coupled monoclonal antibodies (mAbs) were used, allowing double and triple fluorescence analysis:
purchased from Immunotech (Marseille, France), and NKG2-D (IgG1) from R&D Systems (Abingdon, UK). Cells were incubated for 20 min at 41C, washed twice with PBS and fixed before analysis on a FACS-Sort (Becton Dickinson, Pont de Claix, France). Background levels were measured using isotypic controls. For two-and three-color labeling analysis, compensation was set up with single-stained samples. Low forward scatter elements (red cells or debris) were excluded from the analysis and 10 000 events were collected and analyzed using the Cellquest software (Becton Dickinson).
Cytotoxicity assays
PBMCs and immunoselected NK cells were tested for cytotoxicity against the NK-sensitive K562 cell line by means of a 4-h 51 chromium-release assay. Effector to target ratios ranged from 30:1 to 10:1 for PBMC, and from 20:1 to 1:1 for immunoselected NK. All determinations were performed in triplicate and percentage lysis was determined as described previously. 23 In order to normalize the results of consecutive experiments, lytic units (LU) were calculated as described by Pross et al. 24 One LU was defined as the number of effector cells required for 30% lysis of 3 Â 10 3 target cells and the number of LU present in 10 6 effector cells was calculated using a computer program.
Detection of apoptosis
The rate of spontaneous apoptosis was assessed from freshly isolated MDS and donor NK cells, using Annexin V FITCconjugated (Bender Medsystems) to determine phosphatidylserine exposure and DAPI staining to assess cell viability. For confocal microscopy analysis, cells were attached on microscope slides coated with poly-L-lysine (Sigma Diagnostics, Saint Louis, MO, USA), fixed with 4% para-formaldehyde in PBS for 15 min, washed three times with PBS and permeabilized with 0.1% sodium dodecylsulfate in PBS for 10 min. Non-specific sites were blocked with 10% FCS in PBS for 20 min before staining with anticytochrome c antibody (mouse IgG1, BDBiosciences, Pont de Claix, France) for 60 min and washed three times in PBS. Then, cells were incubated for 45 min with Alexa Fluor 546 goat antimouse secondary antibodies (Molecular Probes, Eugene, OR, USA), washed three times in PBS and nuclei were stained by incubation for 10 min with Sytox Green (Molecular Probes, Eugene, OR, USA). The coverslips were mounted using a drop of mowiol and examined under a Zeiss LSM 510 microscope in the confocal mode. Positive controls for apoptosis included donor NK cells incubated with staurosporine. NK cells were grown in liquid culture in the presence of IL-2 (see above) and cell were counted and viability was assessed by trypan blue coloration after 2, 5 and 7 days of culture.
Fluorescence in situ hybridization (FISH)
Freshly immunoselected NK cell populations from MDS patients were allowed to adhere on polylysinet glass slides (O Kindler GmbH, Freiburg, Germany), and fixed in ethanol/acetic acid (3:1) for 30 min. Interphase FISH was performed following the manufacturer's instructions by using the following probes: a rhodamine and fluoescein labeled dual probe (D7Z1/D8Z1) for simultaneous detection of the chromosome 7 and 8 centromere (Qbiogene, Illkirch, France); a spectrum orange and spectrum green labeled probe (LSI EGR1, 5q31/D5S23-D5S721) for simultaneous detection of the chromosome 5 regions 5q31 and 5p15.2; and a spectrum orange and spectrum green labeled probe (LSI D7S486, 7q31/CEP 7) for simultaneous detection of the chromosome 7 region 7q31 and centromere (all from Vysis Inc., Maurens-Scopont, France). Nuclei of cells were counterstained by DAPI (Vectashield, Vector Laboratories Inc., Burlingame, USA). Fluorescent probes were analyzed with an epifluorescent microscope run by the FW4000 software (Leica, Berlin, Germany). In all, 200 cells were counted per specimen by independent observation.
Results
Expression of activating NK receptors by peripheral MDS NK cells is normal
The patients included in the present study are listed on Table 1 . First, the distribution of lymphoid populations in PBMC was compared between MDS patients (n ¼ 40) and healthy donors (n ¼ 10), and did not reveal significant difference regarding CD3 þ (58%, range 15-82), CD4 þ (38%, range 8-50) and CD8 þ (26%, range 8-68). By using the three-color CD56PECy5/CD16PE/CD3FITC combination to quantify the NK cell population, it was shown that the relative and absolute numbers of MDS-NK cells (14%711) were within the normal range (5-20% of lymphocytes).
To further characterize the MDS-NK cells, the percentages and expression level of activating receptors (NCR, NKG2D) were studied on NK cells gated on PBMC using the CD3-FITC:CD56-PECy5 combination. In the series of nine donors, NKp46, NKp30 and NKG2D were expressed by 89% (711.4%), 73% (720.3%) and 96% (72.6%) of NK cells, respectively. Of the 17 MDS patients, 16 displayed a percentage of NKp46 þ NK cells comparable to that observed on donor NK cells (mean 84719%) and one exhibited a reduced percentage (o50% of the mean value of donor NK cells) (Figure 1a) . The percentages of NKp30 varied among patients (mean 66.5729.7%). It is of note that two patients displayed a reduced percentage of positive cells (values o50% of mean value of donor NK cells) whereas MFI was normal (Figure 1a) . The expression of NKG2D by MDS-NK cells (mean 9378.6%) was comparable to that of donor NK cells (mean 9672.6%, Figure 1a) . Mean fluorescence intensity for the three triggering NK receptors were similar in donor and MDS NK cells (Figure 1b) . 
MDS-NK cell cytolytic activities and cytokine secretion are decreased
Functional analysis as performed using MDS-NK cells derived from untreated patients in order to avoid the possible effect of therapeutic agents on NK cell function. For this purpose, resting PBMC, LAK cells (IL-2 activated PBMC for 24 h) and immunoselected NK cells from MDS patients and donors were used as effectors to measure cell-mediated cytotoxicity towards the susceptible target K562.
First, we show that the basal NK-mediated cytolytic activity exerted by MDS PBMC patients was deeply decreased in comparison to that obtained with normal PBMC (Figure 2a) . Interestingly, we noticed that RAEB-1 and RAEB-2 patients had a lower baseline NK activity than RA and RARS patients. It should be noted that no correlation between NK cell-mediated cytolysis and cytogenetics was found. As it is known that NK cells require activation to express their full lytic potential, we compared lymphokine (IL-2) activated killer (LAK) activity of MDS PBMC to LAK activity from donors. Following a short-term activation with IL-2 (500 U/ml, 24 h), a mild increase of lytic activity was observed in MDS samples, but MDS-derived activated PBMCs displayed a much lower LAK activity than that of donors (Figure 2a) .
We have also examined immunoselected NK cell function from MDS patients and donors after activation with IL-2 for 2-7 days. In these functional assays, only cultures of immunoselected NK cells that generated 480% of NK cells (determined as CD3-/CD56 þ cells), contaminated with o10% of CD3 þ T cells were used. IL-2 activated MDS-NK cells displayed a profoundly altered cytolytic function compared to that of activated donor NK cells. As depicted in Figure 2b , the mean lytic activity of activated NK cells measured by lytic units (LU) in 14 MDS patients was significantly reduced compared to than in a series of 10 healthy donors (mean LU: 3287277 versus 17297531, Po0.0001). This defect was observed in all tested WHO subtypes of MDS and remained stable when tested on sequential occasions (Pt 22, 125 versus 152LU, Pt 23, 320 versus 502LU, at 3 months intervals). Altogether these results indicate that despite a high expression of NCR, NK cells derived from all MDS subtypes exhibit a deeply altered cytolytic function (Figure 1b) . The decreased LAK and NK specific lytic activities suggest that a common activation pathway to T and NK cells may be altered in these effectors.
In addition, there was a clear decreased secretion of both IFNg (62 versus 232 pg/ml, P ¼ 0.0079) and TNFa (7.3 versus 80 pg/ ml, P ¼ 0.0035) in MDS-NK cell cultures (n ¼ 17) as compared to donor NK cell cultures (n ¼ 4) in response to IL-2 stimulation (Figure 1c ). in culture. In contrast, the MDS-NK cells grown in vitro died within 7-10 days of culture (n ¼ 25).
MDS-NK cells do not proliferate and exhibit increased apoptosis following in vitro stimulation by cytokines
To further investigate the altered in vitro proliferation of MDS-NK cells, the level of spontaneous apoptosis ex vivo was determined by flow cytometry using AnnexinV/DAPI staining that measures the plasma membrane phosphatidylserine exposure preceding nuclear DNA degradation. 25 NK cells from 17 MDS patients (470% of CD3-CD56 þ NK cells) and 10 donors were studied. The mean percentage of AnnexinV þ MDS-NK cells (measured on CD56 þ CD3-gated cells) was 11% (range 3-22%), not significantly different of the 7.3% (range 3-12%) Annexin V þ NK cells derived from healthy donors (P ¼ 0.1272) (Figure 3a) . It is noteworthy that 5/17 MDS NK cells exhibited a percentage of apoptosis 415%. However, marked differences in apoptosis developed along culture duration between MDS and donor NK cells. NK cell cultures from three MDS patients and three donors were sequentially examined for the early steps of apoptosis by studying cytochrome c release and nuclear changes by confocal microscopy (Figure 3b) . A higher rate of cells displaying cytochrome c realease was detected in MDS-NK cells that was gradually and dramatically increased throughout the culture period. After 7 days, 40-92% of MDS-NK cells were apoptotic, versus only 11-15% of normal NK cells (Figure 3c ). Furthermore, although donor NK cells proliferate after the first days of culture, the percentages of surviving MDS-NK cells rapidly decreased following in vitro stimulation by IL-2. At 5-7 days after the initiation of the cultures, all donors NK cell cultures proliferated, whereas numbers of MDS-NK cells decreased as depicted in Figure 3d . These results clearly show that MDS-NK cells do not expand in vitro following activation with high doses of IL-2 and are gradually eliminated through apoptosis.
Clonal peripheral NK cells are present in MDS patients
Clonality of ex vivo NK cells derived from three informative MDS patients was assessed by FISH analysis. Immunoselected peripheral CD3-/CD56 þ NK cells with a purity of 480% were generated from patients with either the 5qÀ, 7qÀ or þ 8 chromosomal aberration. The number of aneuploid NK cells ranged from 25% in NK cells obtained from the 7qÀ patient, to 41% in NK cells derived from the þ 8 patient and to 44% in NK cells isolated from the 5qÀ patient, respectively. This indicates that both NK cells derived from the MDS clone and normal progenitors coexist in peripheral blood of MDS patients (Figure 4 ).
Discussion
The possible role of the immune system in the development of cytopenias and evolution to AML in MDS, and the potential role of NK cells in cellular immunotherapy led us to study NK cell phenotype and function in MDS patients. This is to our knowledge, the first report on a detailed analysis of the NK function in MDS patients, including determination of natural cytotoxicity receptors (NCR) expression, cytolytic function and survival/proliferation of purified NK cells ex vivo and in response to IL-2 activation.
Although heterogeneous, percentages and absolute numbers of circulation of MDS-NK cells were within the normal range. The expression of NCR was similar to that of donor peripheral NK cells in most MDS patients analyzed. There was, however, a clear discrepancy between peripheral NK cell phenotype and their lytic functions because despite normal NCR expression, baseline MDS-NK-mediated lytic activity was deeply decreased compared to that in healthy donors. These results are intriguing because NK-mediated cytolysis is usually correlated with the NCR expression. 17 However, similar data obtained using immunoselected NK cells before their in vitro activation ensured that NK-mediated cytolysis was indeed measured.
Furthermore, the cytolytic activity of IL-2-activated MDS-NK remained profoundly altered, exhibiting a 10 times decreased lytic potential compared to that in donors NK cells, extending previous results obtained using bulk population.
9,10 A recent study in AML patients showed a reduced NCR expression by NK cells correlated as expected with the altered lysis of leukemic blasts on peripheral NK cells. 26 It may thus be assumed that different mechanisms control the NK development and function in these two myeloid pathologies with an altered response to activation in MDS NK cells. This is the first report describing the existence of human NK cells with an altered cytolytic activity despite NCR bright phenotype. It is interesting to note that LAK activity (mainly CD3 þ T-cell mediated) as well as purified NK cell-mediated lysis were deeply decreased in MDS samples suggesting a functional alteration of these two effectors following cytokine activation. These results obtained on purified NK cells extend previously published studies of NK cell function in IL-2-treated MDS patients. 27, 28 Alteration of NK cells cytolysis has been previously related to increased seric soluble MIC-A molecules that bind to NKG2D receptor and inhibit its signaling. 29 This mechanism is probably not implicated in the functional anergy of MDS-NK cells, as soluble MIC molecules were undetectable in 13/15 MDS sera and very low in 2/15 MDS sera (data not shown). Signal transduction of NCR (NKp46 and NKp30) involves CD3zeta chain phosphorylation whose expression is often decreased in tumors and leukemia. 30 It was also shown recently that pp65 from CMV can inhibit the NKp30 signaling by direct by binding to the NCR, altering CD3z association. 31 In MDS, the expression of CD3z was normal in LAK and activated NK cells (data not shown) in contrast with findings in chronic myelogenous leukemia, 32 excluding CD3z chain alteration as a cause of the functional defect observed.
The second major finding of our study was an altered in vitro proliferation of MDS NK cells in response to stimulation by IL-2. The rate of spontaneous apoptosis was not significantly increased in MDS compared to donors NK cells but the initial in vitro activation-induced apoptosis was not compensated by active proliferation in response to high doses of IL-2. This contrasts with the successful in vitro expansion of peripheral NK cells from chronic lymphocytic leukemia patients as the numbers of NK cells were amplified 50-500-fold in the eight cases reported. Furthermore, those CLL-derived NK cells had a cytolytic function comparable to control NK cells. 33 The presence of immunosuppressive factors in the sera of MDS patients could explain the functional defects and the lack of in vitro proliferation of IL-2-activated MDS-NK cells. For example, elevated circulating levels of TNF have been reported in MDS patients, 34 which may alter the baseline cytolytic activity of circulating MDS-NK cells. A recent study outlined the role of NCR in the control of NK cell suicide through Fas-FasL engagement following interactions between NK and tumor targets cells. 35 Thus, NCR engagement by target cells on IL-2-activated NK cells could be an alternative mechanism for increased apoptosis in MDS. This is the first report of enhanced apoptosis of IL-2-activated MDS-NK cells. Furthermore, this phenomenon was observed in (Pts 22, 39, 40) , with either the 5qÀ, 7qÀ or þ 8 anomaly were subjected to FISH analysis as described in Materials and methods. Red spots indicate the presence or absence of the 5q31 or 7q31 region, respectively, whereas green spots stain for the centromere of chromosome 8. In all, 200 cells per specimen were analyzed by fluorescence microscopy (63-fold magnification). One out of three independent experiments is shown. MDS, diseases characterized by enhanced apoptosis of myeloid bone marrow progenitors. Although evidence for clonality has been found in all forms of MDS, the nature of the hematopoietic stem cell involved (committed or multipotent) has not been clearly established. 36, 37 Abnormal myelopoiesis is a hallmark of MDS but several reports, based on cytogenetic analysis, showed that MDS-NK cells may exhibit the same chromosomal anomaly as myeloid progenitors. 38, 39 In the present study, by FISH analysis of immunoselected MDS-NK cells derived from informative patients, we provided evidence that 30-50% of NK cells displayed the cytogenetic anomaly existing in myeloid cells. However, abrogation of the lytic potential and the absence of proliferation of MDS-NK cells in vitro possibly involved the total NK pool resulting in global 'anergy' as the percentages of clonal NK cells was o50%.
The altered lytic and proliferative capacities of peripheral NK cells following cytokine activation were observed in all the MDS samples regardless of the WHO subtype, clinical characteristics of patients or bone marrow cytogenetics, suggesting that cytotoxic effectors (NK, LAK) alteration in MDS could play a role in the pathophysiology and progression of the disease. Surprisingly, this NK defect did not have clinical impact on infections rate. In our series, viral infection possibly controlled by NK cells were rare and NK defect was not associated with increased bacterial and fungal infection in non-neutropenic patients. It may also be hypothesized that an immune modulation with exogeneous cytokines to induce proliferation and activation of non-specific cytotoxic effectors would probably not be an effective therapeutic strategy in MDS patients. Such results may also explain the poor response rate of MDS patients to therapeutic trials with IL-2, 40 which were based on previous studies reporting the enhancement of LAK activity with IL-2 in MDS samples. 41 
